Status:
COMPLETED
Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine
Lead Sponsor:
Novartis Vaccines
Conditions:
Prevention of Meningococcal Infection
Eligibility:
All Genders
12-13 years
Phase:
PHASE4
Brief Summary
Persistence of antibodies and kinetics of B cell response in healthy children after vaccination with MCC vaccine
Eligibility Criteria
Inclusion
- Healthy children
Exclusion
- Known hypersensitivity to any vaccine products
- Any immunodeficiency, genetic anomaly or severe acute or chronic illness
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2006
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT00310713
Start Date
April 1 2006
End Date
August 1 2006
Last Update
September 19 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road
Headington, Oxford, United Kingdom, OX3 7LJ